Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.40 |
| ▸ | FAAH | O00519 | 5/20 | 0.39 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803876 | 0.81 | FFAR4 (0.49) | FFAR4FFAR1PDE4DFAAHPDE4A | |
| SCHEMBL3803873 | 0.81 | FFAR4 (0.49) | FFAR4FFAR1PDE4DFAAHPDE4A | |
| SCHEMBL2680595 | 0.81 | FFAR4 (0.49) | FFAR4FFAR1PDE4DFAAHPDE4A | |
| SCHEMBL2682323 | 0.74 | FAAH (0.49) | FFAR4FFAR1PDE4DFAAHPDE4A | |
| SCHEMBL2681877 | 0.73 | ENPP2 (0.48) | FFAR4FFAR1PDE4DPDE4APDE4B | |
| SCHEMBL3793378 | 0.73 | ENPP2 (0.48) | FFAR4FFAR1PDE4DPDE4APDE4B | |
| SCHEMBL14658591 | 0.70 | FFAR1 (0.46) | FFAR4FFAR1PDE4DPDE4APDE4B | |
| SCHEMBL2681413 | 0.70 | FFAR1 (0.47) | FFAR4FFAR1PDE4D | |
| SCHEMBL24845193 | 0.68 | CYP4F2 (0.46) | FFAR4FFAR1 | |
| SCHEMBL24844914 | 0.68 | CYP4F2 (0.46) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664253-B2 | Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents | MERCK SHARP & DOHME CORP (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
| US-20120115894-A1 | IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115894-A1 | IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS | FAAH, FAAH2, INMT | FFAR4 13/4885FFAR1 56/4885PDE4D 393/4885 |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | FAAH, FAAH2, CNR2 | FFAR4 134/4885FFAR1 194/4885PDE4D 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.